MBX Biosciences, Inc. (MBX) Stock Price & Analysis
MBX Biosciences, Inc. (MBX) closed at USD 50.46 on Thursday, October 22, 2026, down 6.43% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 53.93; the Oct 22, 2026 session ranged USD 50.25–54.99 on volume of 631,689 shares. Market capitalization is $2.43B, with a 52-week range of USD 14.61–72.64 (NMS). Source: Nexqual, retrieved October 23, 2026 at 10:12 UTC.
Also available as compact Markdown for AI agents: nexqual.com/MBX.md
Key facts (MBX)
- Analysts: Buy (mean 1.73 on a 1–5 scale) (11 analysts), mean target USD 95.7 (range 80–150).
- Total return with dividends: 1Y +212.8% vs S&P 500 +14.9%; 5Y +113.4% vs S&P 500 +80.3%.
- Next earnings: 2026-11-05, EPS estimate USD -0.84, revenue estimate $0K.
Analysts (MBX)
Consensus Buy (mean 1.73 on a 1–5 scale), 11 analysts; mean target USD 95.7 (low 80, high 150).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-12 | Stifel | Target raised | Buy | $70 → $84 |
| 2026-10-02 | Guggenheim | Target raised | Buy | $88 → $150 |
| 2026-08-10 | Truist Securities | Target raised | Buy | $70 → $88 |
| 2026-07-29 | Mizuho | Target raised | Outperform | $57 → $91 |
Total return (dividends reinvested) (MBX)
| 1Y (from 2025-10-23) | 5Y (from 2024-09-09) | |
|---|---|---|
| Total return | +212.8% | +113.4% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +214.1% | +43.0% |
| Volatility (annualized) | 77.0% | 97.0% |
| Max drawdown | -37.6% (Jan 2026→Mar 2026) | -74.9% (Oct 2024→Mar 2025) |
MBX analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $-0.84 | $-0.74 | +14.4% | $0 | 7 |
| Next quarter (ends Dec 2026) | $-0.93 | $-0.84 | +10.7% | $0 | 7 |
| Current fiscal year (ends Dec 2026) | $-3.05 | $-2.75 | +11.1% | $0 | 8 |
| Next fiscal year (ends Dec 2027) | $-3.98 | $-3.93 | +1.2% | $0 | 8 |
Key Statistics (as of October 23, 2026 at 10:12 UTC)
| Price | USD 50.46 |
|---|---|
| Change | ▼ 6.43% (down) |
| Previous Close | USD 53.93 |
| Open | USD 53.5 |
| Day Range | USD 50.25 – 54.99 |
| 52-Week Range | USD 14.61 – 72.64 |
| Volume | 631,689 shares |
| Market Cap | $2.43B |
| Exchange | NMS |
Technical Analysis (MBX)
Nexqual's technical model rates MBX "STRONG SELL" based on 0 bullish and 5 bearish signals across 127 daily candles, as of October 23, 2026 at 10:12 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 38.96 (neutral) |
| vs SMA50 | Below (USD 59.6) |
| MACD | -2.29 (negative) |
Analyst Ratings (MBX)
Wall Street analysts rate MBX "Buy" based on 11 analysts, with a mean price target of USD 95.7 (range USD 80–150), per Nexqual as of October 23, 2026 at 10:12 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 11 |
| Mean Target | USD 95.7 |
| High Target | USD 150 |
| Low Target | USD 80 |
| Buy / Hold / Sell | 11 / 0 / 0 |
Earnings (MBX)
| Next Earnings Date | 2026-11-05 |
|---|---|
| EPS Estimate | USD -0.84 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.78 vs est -0.59 ▼ miss |
| 2026-03-31 | USD -0.51 vs est -0.58 ▲ beat |
| 2025-12-31 | USD -0.49 vs est -0.6 ▲ beat |
| 2025-09-30 | USD -0.63 vs est -0.68 ▲ beat |
Source: Nexqual, October 23, 2026 at 10:12 UTC.
Financials & Fundamentals (MBX)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -33.17% |
| Debt / Equity | 0.01 |
| Current Ratio | 18.08 |
| Total Cash | $418.58M |
| Total Debt | $3.34M |
Source: Nexqual, October 23, 2026 at 10:12 UTC.
Financial Health Score (MBX)
Nexqual rates MBX Biosciences, Inc.'s overall financial health "Mixed" across five dimensions, as of October 23, 2026 at 10:12 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $419M cash vs $3M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$80M (FY ended Dec 2025, 10-K) |
| Efficiency | Critical — ROE -33%, ROA -22.1% |
Ownership (MBX)
| Insider Ownership | +2.88% |
|---|---|
| Institutional Ownership | +116.06% |
| Shares Outstanding | 48.16M |
| Float | 30.99M |
| Short % of Float | +12.95% |
Source: Nexqual, October 23, 2026 at 10:12 UTC.
Leadership (MBX)
MBX Biosciences, Inc. is led by Steven L. Hoerter, Executive Chairperson, CEO & President, per Nexqual as of October 23, 2026 at 10:12 UTC.
| Executive Chairperson, CEO & President | Steven L. Hoerter |
|---|---|
| Chief Financial Officer | John W. Smither |
| Senior Vice President of Investor Relations & Corporate Communications | Pete De Spain |
| Sr. Vice President of Discovery & Non-Clinical Development | Michael A. Dorato DABT |
| Senior Vice President of Clinical Development | Andreas Moraitis |
Major Backers & Investors (MBX)
Notable institutional backers of MBX Biosciences, Inc. include Frazier Life Sciences Management, L.P. , FMR, LLC, Wellington Management, according to Nexqual as of October 23, 2026 at 10:12 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Frazier Life Sciences Management, L.P. | 13.81% |
| FMR, LLC | 11.05% |
| Wellington Management | 10.34% |
| NEA Management Company, LLC | 7.51% |
| Orbimed Advisors LLC. | 7.12% |
| Fidelity | 6.75% |
| Paradigm Biocapital Advisors LP | 5.21% |
| NVP Associates, LLC | 4.44% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 6.9% |
Source: Nexqual, October 23, 2026 at 10:12 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| LGND | Ligand Pharmaceuticals Incorpor | USD 307.82 | ▼ 2.21% |
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 90.9 | ▲ 2.57% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.14 | ▼ 3.28% |
| PRAX | Praxis Precision Medicines, Inc | USD 258.92 | ▲ 0.96% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 43.91 | ▼ 0.81% |
| ABVX | Abivax SA | USD 90.23 | ▼ 3.49% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 10:12 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt